ONLINE SUBMISSION
  February, 2013

Serum Leptin values in the healthy obese and non-obese subjects of Rawalpindi

  Ahsan Kazmi  ( Pathology Department, Rawalpindi Medical College (NTB), Holy family Hospital, Rawalpindi. )
Abdus Sattar, Rizwan Hashim, Shahida Parveen Khan, Mohammad Younus, Farooq Ahmed Khan  ( Chemical Pathology and Endocrinology Department, Armed Forces Institute of Pathology, Rawalpindi. )
 

Introduction

Leptin1 is a protein hormone that plays a key role in regulating body weight and metabolism. It was discovered in 1994. Its discovery has generated much attention in the fields of obesity and metabolic research.
Leptin molecule is approximately 16 kDa and encoded by the obesity (ob) gene. It is synthesised and secreted by adipocytes, and serum concentrations reflect the amount of energy stored in adipose tissue.2 Leptin binds to receptors in the hypothalamus and influences the expression of several neuro-peptides that regulate energy intake, energy expenditure, and neuro-endocrine functions, thereby decreasing bodyweight. Genetically obese mice have mutations of ob gene with resultant very low levels of leptin. Similarly, few persons with extreme genetic obesity are leptin-deficient. However, most obese persons have hyperleptinaemia proportionate to body fat and appear to be leptin-resistant.2 The physiologic role of leptin is presently not completely understood. It may be a determinant of obesity and its complications. Limited studies have been conducted to explore the relation of leptin concentrations with Body Mass Index (BMI) in local population.3-6 Leptin may have an effect on BMI. A few studies conducted in Pakistan included finding correlations of leptin with certain diseasee or determining serum leptin levels in cord blood.7 To increase our understanding about the relationship of leptin concentrations with BMI, age and gender in the population of Rawalpindi, Pakistan, we measured serum leptin concentrations in 100 obese and non-obese healthy subjects of both genders in a sample of adult population of Rawalpindi.


Subjects and Methods

The observational, comparative study was conducted at the Armed Forces Institute of Pathology (AFIP), Rawalpindi, and the Benazir Bhutto Hospital (BBH) Rawalpindi from August 2008 to December 2008.
The study initially comprised 100 healthy obese and non-obese subjects who were picked by non-probability sampling. Among them, 50 were healthy obese, including overweight, and 50 healthy non-obese, between 20 and 50 years of age. The subjects were labelled overweight (BMI= 23.1-27.4kg/m2); obese (27.5-40kg/m2) and non-obese (18.5-23.0kg/m2). The BMI values were used under the guidelines for Asian populations issued in 2000 by the International Association for the Study of Obesity and the International Obesity Task Force of World Health Organisation, Western Pacific Region, Australia.8,9 Very obese subjects having BMI >40kg/m2 and pregnant female subjects were excluded from the study. The study was approved by the AFIP ethical committee, and a verbal informed consent was obtained from all the participants.
Relevant clinical and laboratory data was collected from healthy obese and non-obese attendants of patients who presented at the outpatient department in BBH and the reception of AFIP. The data was entered in a peroforma. Clinical history was taken about diabetes mellitus, hypertension, depression or any acute or chronic disease to exclude such subjects from the study. Subsequently the subjects having fasting plasma glucose 126 mg/dl were excluded. The final sample size, as such, stood at 90.
For BMI, height (cms) was measured using wall-mounted stadiometer and weight (kg) was determined using a weighing balance. BMI was calculated by the following formula: BMI= Weight (kg)/ Height (m2).
After an overnight fast, blood samples were obtained in the morning between 0800-0900 hours. Blood samples were poured into plain tubes and allowed to clot at room temperature. The serum for leptin was separated 20 minutes after collection by centrifugation at a speed of 2000-3000 G for 10 minutes. Serum samples were aliquoted and frozen at -20°C for analysis later on.
The quantitative determination of serum leptin was conducted by Sandwich Enzyme-Linked Immunosorbent Assay (ELISA) technique, using commercially available reagent kit, DRG® Leptin (Sandwich) ELISA (EIA-2395) by RUO, Germany.
All statistical analyses were performed using SPSS 15. For each variable, mean, standard deviation, and ranges were calculated. P values for comparison of serum leptin level were determined in healthy obese and non-obese subjects; p <0.05 was considered significant. For correlation between serum leptin and BMI in healthy obese and non-obese subjects, r-values were determined by Pearson\'s correlation test.


Results

Comparison of baseline characteristics in terms of age, height, weight, BMI, fasting plasma glucose, and serum leptin levels of the subjects was noted (Table-1).


The mean age in the obese (n=40) and the non-obese (n=50) groups was 34.8±4.6 years (range 30.2-39.4 years) and 32.7±6.1 years (range 26.6-38.8 years) respectively. There were 33 (66%) females in the obese and overweight group, and 32 (64%) females in the non-obese group (p= 0.834) (Figure-1).

The mean height in obese and non-obese groups was 163±6.7cms (range 156.3-169.7cms) and 167±6.7cms (range 156.3-173.7cms) respectively. Mean weight in obese and non-obese groups was 80±9.7 kg (range 70.3-89.7kg) and 59±6.6kg (range 52.4-65.6kg) respectively. Both the groups were comparable with respect to age, gender and weight/BMI. Age of the subject had no significant effect on fasting serum leptin levels in both the groups (p= 0.416).
Mean BMI and serum leptin levels were compared in male and female obese and non-obese subjects, which showed significant differences. The mean serum leptin concentration was much higher in healthy obese and non-obese women (64.4 ng/mL & 8.7 ng/mL respectively) compared with men in these groups (40.4 ng/mL & 5.5 ng/mL respectively).
Highly significant difference was observed between mean BMI of obese and non-obese groups. Mean BMI in obese group was 31.7±3.1kg/m2 (range 28.6-34.8 kg/m2), while it was 21.2±1.5kg/m2 (range 19.7-22.7kg/m2) in the non-obese group. Similar was the difference between mean serum leptin level (52.8±24.6ng/dl, range 28.2-77.4ng/mL) in the obese group and (6.3±3.1ng/dl, range 6.6-18.8ng/mL) in the non-obese group. Highly significant correlation between serum leptin level and BMI was found (r= 0.59, p= 0.001) (Figure-2).

The mean serum leptin level in overweight subjects was in between that of obese and non-obese groups and it also correlated well with BMI.


Discussion

The study found a strong relationship between BMI and serum leptin in the obese group. Serum leptin level was significantly higher in obese than non-obese subjects. This was in agreement with some previous studies.5,10 Maffei et al measured serum leptin levels in obese and weight-reduced subjects. In the present study, the same was done in apparently healthy obese and non-obese subjects (normal healthy adults).10 In another study conducted by Considine et al,2 serum leptin concentration were measured by using radioimmuno-assay in 136 normal-weight subjects and 139 obese subjects (BMI >27.3 for men and >27.8 for women). In the present study, serum leptin was measured using Sandwich ELISA technique in 100 obese and non-obese subjects. The advantage of present study is that it was more specific, as the chance of cross-reactivity to other biological products of human origin was nil. Cross-reactivity with mice leptin is 0.2% (manufacturer\'s data), which is negligible. In the above-mentioned study, the mean serum leptin concentrations were 31.3±24.1ng/mL in the obese subjects and 9.3±7.5ng/mL in the normal-weight subjects (p <0.001). In the present study, these were 52.8±24.6ng/mL in the obese subjects and 6.3±3.1ng/mL in the normal-weight subjects (p <0.001). The leptin concentration was relatively much higher in obese subjects in the present study than that of Considine et al.2 This may be due to different methods of analysis and/or study population. Our results showed significantly low levels of serum leptin levels, signifying more accuracy at lower values of the assays. Similar is the case with high levels of leptin. This means that our method had better linearity and detection limit; it could detect leptin both at low and high levels (range from 0-100 ng/mL in serum).
Serum leptin concentrations were not related with age in this group (20-50 years, P= 0.416). However, serum leptin concentrations were found higher in females than males in the same age group and BMI level. Panarotto et al, observed that for a given bodyweight, the levels were higher in women than in men, but the reason for this difference was not clear.11 This may be due to greater amount of percent body fat mass in females or the inducing effects of oestrogen-progesterone combined with suppressive effects of androgens on leptin.12 Our observation is also in agreement with some other international studies5,13-15 in which serum leptin levels were found to be higher in females.
A small sample size and convenience sampling were used in this study which was a limitation of the exercise. More studies with larger sample size and different sampling technique may be planned to find out the relationship between serum leptin and BMI.


Conclusions

In this sample of Rawalpindi population, BMI strongly correlated with serum leptin concentrations in healthy obese and non-obese subjects of either gender. Moreover, serum leptin concentrations were found to be higher among the females. There was no significant relationship between age and serum leptin level in this age group.


Acknowledgements

We are grateful to M.Phil trainees Dr. Nowshad Asim and Dr. Sonia Aziz as well as the participants and the staff of the chemical Pathology and Endocrinology Department, AFIP, especially Mr Abbas, for their assistance and cooperation.


References

1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
2. Considine RV, Sinha MK, Heiman ML, Kriauciunos A, Stephens TW, Nyce MR. Serum Immunoreactive- leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5.
3. Lakho GR, Haq Z, Akber J, Chundrigar T, Qureshi MA. Relationship between maternal and cord blood leptin levels in Pakistani subjects. Pak Paed J 2006; 30: 95-100.
4. Lakho GR, Haq Z, Chundrigar T, Nazir K, Qureshi MA. Cord blood Leptin levels in Pakistani newborns: relationship with birth weight, length and occipitofrontal circumference. J Coll Physicians Surg Pak 2006; 16: 393-5.
5. Ramachandran A, Snehalatha C, Vijay V, Satyavani K, Latha E, Haffner SM. Plasma leptin in non-diabetic Asian Indians: association with abdominal adiposity. Diabet Med 1997; 14: 937-41.
6. Haque Z, Ata-ur-Rahman. Serum leptin levels in female patients with NIDDM.J Coll Physicians Surg Pak 2003; 13: 130-4.
7. Bennett FI, McFarlane-Anderson N, Wilks R, Luke A, Cooper RS, Forrester TE. Leptin concentration in women is influenced by regional distribution of adipose tissue. Am J Clin Nutr 1997; 66: 1340-4.
8. Choo V. WHO reassesses appropriate body-mass index for Asian populations. Lancet 2002; 360: 235.
9. Tim Gill. Epidemiology and health impact of obesity: an Asia Pacific perspective. Pac J Clin Nutr 2006; 15 (Suppl): 3-14 3.
10. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, et al. Leptin levels in human and rodent; measurement of plasma leptin and ob RNA in obese and weight reduced subjects. Nature Med 1995; 1: 1155-61.
11. Panarotto D, Ardilouze JL, Tessier D, Maheux P. The degree of hyperinsulinemia and impaired glucose tolerance predicts plasma leptin concentrations in women only: a new exploratory paradigm. Metabolism 2000; 49: 1055-62.
12. Shimizu H, Shimomura Y, Nakanishi Y, Futawatari T, Ohtani K, Sato N, et al. Estrogen increases in vivo leptin production in rats and human subjects. J Clin Endocrinol Metab 1997; 154: 285-92.
13. Rosenbaum M, Nicolson M, Hirsch J, Heymsfield SB, Gallagher Chu F, et al. Effects of gender, body composition, and menopause on plasma concentration of leptin. J Clin Endocrinol Metab 1996; 81: 3424-7.
14. Weimann E, Blum WF, Witzel C, Schwidergall S, Bohles HJ. Hypoleptinemia in female and male elite gymnasts. Eur J Clin Invest 1999; 29: 853-60.
15. Ruhl CE, Everhart JE. Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr 2001; 74: 295-301.


News & Events

WHO/GOARN Request for technical assistance for Cholera Control in Northern Iraq

Request for assistance

WHO is requesting assistance from GOARN partners to identify the following cholera and diarrhoeal diseases expertise to support the Ministry of Health of Iraq in cholera risk assessment and immediate preparedness activities to improve the health outcomes of the Syrian refugees current living in camps in the Kurdistan region of Iraq.

  • two (2) epidemiologists
  • two (2) clinical management experts
  • one (1) environmental health expert (WATSAN)
  • one (1)laboratory expert

Duration

6 day mission starting 13 June 2014 (this excludes travel time).

Location

Northern Iraq (Kurdistan region).

Language requirements

All candidates must be fluent in English- written, spoken and comprehension. Fluency in Arabic is an asset. Knowledge, abilities and skills All candidates are expected to demonstrate the following

  • Ability to conceptualize and promote innovative strategies and policies.
  • Ability to communicate and write in a clear concise manner, and to develop effective guidelines.
  • Excellent negotiation and interpersonal skills complemented by ability to motivate and lead others and to promote consensus. Tact, discretion and diplomacy
  • Demonstrated ability for project appraisal, project management, monitoring and evaluation and project impact assessment.
  • Ability to work with host governments and their agents, INGOs and national NGOs an advantage.
  • Proven experience of managing a large workload and multiple priorities.
  • Ability to work in difficult conditions.

Support to the mission

WHO/GOARN will cover the travel and per diem (to cover daily expense in the field) expenses for the duration of their mission. GOARN missions do NOT offer salary, consultancy fees or any other form of remuneration.

WHO will provide appropriate logistics support for the field mission. Pre-deployment orientation/training may be required at WHO.

Partners offers of assistance

Partners are requested to reply with offers of assistance, together with CVs and details of the availability of staff for this mission by email to goarn@who.int latest by 30 May 2014. Details of all offers from partners and eventual deployments will be maintained on the GOARN SharePoint.

Operational Contacts

Mamunur Malik WHO EMRO malikm@who.int

William Perea WHO HQ pereaw@who.int

Patrick Drury GOARN druryp@who.int



News



Index



Supplement